



John Lahart, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

27th June 2024

PQ: 26650/24

To ask the Minister for Health to provide an update on the availability of the drug skyrizi (risankizumab-rzaa) for patients with severe Crohn's disease, given the delays due to price negotiations and its current availability in the UK and Europe. -John Lahart

Dear Deputy Lahart,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 26650/24), which you submitted to the Minister for Health for response.

Restricted hospital pricing approval and reimbursement approval under the High Tech arrangements is in place from the 1st April 2024 for Risankizumab (Skyrizi®) for the treatment of adult patients with moderately to severely active Crohn's Disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic therapy.

Reimbursement is restricted to use as a subsequent line of therapy following treatment with a lower cost biologic therapy.

Yours sincerely,

A handwritten signature in black ink that reads 'Suzanne Doyle'.

Suzanne Doyle
Primary Care Eligibility & Reimbursement Service